Home › Funds › Carmignac Gestion › VRTX

Carmignac Gestion position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Carmignac Gestion reported holding 163,285 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$85.4M, representing 1.36% of its reported portfolio and ranking #23 among its reported holdings. Carmignac Gestion has disclosed VRTX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)163.28K sh
Reported value held$85.39M
Portfolio Weight1.36%
First reportedQ2 2024
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Carmignac Gestion's VRTX position evolved

Carmignac Gestion first disclosed a stake in VRTX in Q2 2024 at 185,249 shares (US$86.8M). The position peaked in Q2 2025 at 227,296 shares, worth US$101.2M. Across 10 filings, Carmignac Gestion increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 163,285 shares valued at US$85.4M. Notable position changes include a 36% trim in Q1 2025 (shares fell 8% over the following quarter), a 79% increase in Q2 2025 (shares fell 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 185.25K $86.85M New
Q3 2024 210.52K $97.89M Add
Q4 2024 197.47K $79.49M Reduce
Q1 2025 126.95K $61.61M Reduce
Q2 2025 227.30K $101.16M Add
Q3 2025 187.54K $73.46M Reduce
Q4 2025 191.57K $86.85M Add
Q1 2026 148.20K $66.16M Reduce
Q2 2026 163.04K $81.00M Add
Q3 2026 163.28K $85.39M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Carmignac Gestion held VRTX?

Carmignac Gestion has disclosed VRTX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

What is Carmignac Gestion's current position in VRTX?

As of Q3 2026, Carmignac Gestion holds 163.28K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $85.39M, representing 1.36% of its reported portfolio and ranking #23.

Has Carmignac Gestion been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Carmignac Gestion held unchanged its position in VRTX. The position peaked in Q2 2025 at 227.30K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.